CompletedPhase 2NCT02135536
Phase 2b Study of NGM282 Extended Treatment in Patients With Primary Biliary Cirrhosis
Studying Primary biliary cholangitis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- NGM Biopharmaceuticals, Inc
- Principal Investigator
- Stephen J Rossi, PharmDNGM Biopharmaceuticals, Inc
- Intervention
- NGM282(biological)
- Enrollment
- 36 target
- Eligibility
- 18-75 years · All sexes
- Timeline
- 2014 – 2016
Study locations (17)
- NGM Clinical Study Site 103, Phoenix, Arizona, United States
- NGM Clinical Study Site 108, Coronado, California, United States
- NGM Clinical Study Site 101, Detroit, Michigan, United States
- NGM Clinical Study Site 105, Durham, North Carolina, United States
- NGM Clinical Study Site 102, Dallas, Texas, United States
- NGM Clinical Study Site 113, San Antonio, Texas, United States
- NGM Clinical Study Site 602, Sydney, New South Wales, Australia
- NGM Clinical Study Site 606, Sydney, New South Wales, Australia
- NGM Clinical Study Site 609, Sydney, New South Wales, Australia
- NGM Clinical Study Site 611, Sydney, New South Wales, Australia
- NGM Clinical Study Site 614, Brisbane, Queensland, Australia
- NGM Clinical Study Site 607, Adelaide, South Australia, Australia
- NGM Clinical Study Site 608, Adelaide, South Australia, Australia
- NGM Clinical Study Site 601, Melbourne, Victoria, Australia
- NGM Clinical Study Site 613, Melbourne, Victoria, Australia
- +2 more locations on ClinicalTrials.gov
Collaborators
NGM Biopharmaceuticals Australia Pty Ltd
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02135536 on ClinicalTrials.govOther trials for Primary biliary cholangitis
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07449793Biochemical Response and Clinical Outcomes in Patients With PBCRenJi Hospital
- RECRUITINGPHASE3NCT07296458FIREFLY Trial: Fenofibrate Intervention---Randomized Evaluation in First-Line PBC TherapyXijing Hospital of Digestive Diseases
- RECRUITINGPHASE3NCT07282353A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCACascade Pharmaceuticals, Inc
- RECRUITINGNCT07205874Early Diagnosis of Primary Biliary Cholangitis (PBC) in Patients With Positive Anti-Mitochondrial Antibodies (AMA) and Normal Alkaline Phosphatase (ALP)Hospital Universitario La Paz
- ACTIVE NOT RECRUITINGNCT07049887A Study Describing Scratch and Sleep Patterns in Patients With Primary Biliary Cholangitis (Luminaria)Ipsen
- RECRUITINGNCT07149675PBC Long-term Outcomes StudyBeijing Friendship Hospital
- RECRUITINGEARLY PHASE1NCT07104201Fenofibrate in Subjects With Primary Biliary Cholangitis (PBC)Xijing Hospital of Digestive Diseases
- RECRUITINGNANCT06861465EMPower MechanismsUniversity of Alberta